Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. - Wikidata - wikimedia - TriplyDB

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.

http://www.wikidata.org/entity/Q34004009

about

Progress and problems in understanding and managing primary Epstein-Barr virus infections Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis The role of the Epstein-Barr virus in the pathogenesis of some autoimmune disorders - Similarities and differences Epstein-Barr virus infection and posttransplant lymphoproliferative disorder Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines.Progress, prospects, and problems in Epstein-Barr virus vaccine development.Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge Antibody evasion by a gammaherpesvirus O-glycan shield Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay Epstein-barr virus vaccines.Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.New adjuvants: EU regulatory developments.A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.Immune escape by Epstein-Barr virus associated malignancies.High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.EBV-positive human sera contain antibodies against the EBV BMRF-2 protein.Epstein-Barr virus: novel patented therapeutics.Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation.Towards in silico design of epitope-based vaccines.Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.EBV-related lymphomas: new approaches to treatment.A virus-like particle-based Epstein-Barr virus vaccine.Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.EBV-Associated Cancer and Autoimmunity: Searching for Therapies.Role for HLA in susceptibility to infectious mononucleosis.Epstein-Barr virus in the development of multiple sclerosis.Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.Early Epstein-Barr Virus Genomic Diversity and Convergence toward the B95.8 Genome in Primary Infection.An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.

P2860

Q24597706-1ACBC197-7B32-4888-A8B1-DADF4FE23AED Q24657081-D70A137F-C53C-432D-90EA-E009667812E8 Q26866256-46FD2095-2ACE-4843-991C-094CD311FA25 Q27024229-2E042978-2FDF-4CB2-A6B3-29C445F973B6 Q33344450-B80BD1F4-9A82-4A20-AD23-57C66359F88A Q33396199-96E58F17-7F75-48ED-B2C9-458D542ABE04 Q33812640-FCB1BBE7-C518-48F1-9A8A-C9AE43B540D8 Q34009363-743DF5E1-236E-4A96-8338-4A585F54E048 Q34058118-CA518041-D87D-4748-927D-7EF33E11F2C2 Q34082672-6D98304E-FC4C-4C82-9744-B2D17D15E6C9 Q34609654-6E1A8699-12D7-4C81-AAE7-0296A091405D Q35053650-79945313-203E-4DA9-B2D8-CE848438E735 Q35829978-8F488A5A-7151-485A-A916-B594DA10ACD3 Q35994831-24EC43B3-D396-4181-AB7F-EA336CF39D88 Q36590540-43760446-AF26-4785-A5DF-372E783E2086 Q36764365-E14CA618-61AC-432D-B4E9-1822935C0D3D Q36835091-01A2D8F1-4C5C-4DAC-9532-B08288BC601E Q36968305-DC3879EA-9E5B-435F-BA8D-6C81B35FDFE1 Q36979271-39620497-1A85-47C7-9AD5-A85B490CFDBA Q37041507-2E5F1C7B-684D-4168-9679-8718D46F692D Q37100066-F92304F3-FB65-4B8D-B1E6-03A62C9F6B97 Q37408295-C1E19A29-0D6A-4133-AA0E-50078E242FFA Q37729167-D5B84901-5455-4759-896F-816FE84B0F53 Q37745980-B21DB286-96EC-45D1-BFF3-C1EED11E96E2 Q37888687-F9704874-E8C0-4A39-B715-D63DFDBE9CFF Q38088325-512A3F8E-CF38-4BC3-853C-C57B531B0B53 Q38282075-FE9BFD45-C436-4AF3-8F93-92FA832DDAFB Q38635035-AC5AF7C0-0642-44A2-BEE6-74FD61B284EB Q38735147-63ED432B-771A-47A0-859D-3763659BD12A Q38885776-136199A3-EA7B-4953-9EC6-54E0BE3A5C88 Q39170011-87BCBFDF-785C-40A2-8D26-3196258D725C Q39441281-A78B8CDD-77B6-4584-BB8F-885C3FAB1FD9 Q39458965-59189D04-3D37-463B-AEDA-182D89D4FADD Q40967391-09BA47B9-6249-425F-B4AB-87E64A46C670 Q41012612-1A2E971B-2646-4D02-A48E-076F868BFD5A Q41376086-45748CDE-EE94-427C-8EAD-D04155FE0A0D Q45396442-7F3EFD71-1DD6-40FF-81A4-99CF67D613F9 Q47547404-DFE194E8-C5AD-4936-A342-19784B8A95AB Q47576936-CBA610E5-FDC5-412B-BEDF-833287A23E54 Q52317335-B49DA1B6-AE8D-40DE-AFA3-BB881BC8FAFC

P2860

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.

http://www.wikidata.org/entity/Q34004009

description

2007 nî lūn-bûn

@nan

2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@ast

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@en

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@nl

type

label

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@ast

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@en

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@nl

prefLabel

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@ast

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@en

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@nl

P1433

Q34004009-F43F6D2F-B097-468B-9AB8-A2122654068D

P1476

Q34004009-2F7890FD-376B-40EA-BA7B-63E23F2EDEEF

P2093

Q34004009-05EB33D1-342D-4650-812A-CFF59E338BCE

Q34004009-093EECAE-7522-4A95-A36A-AFC103AE5B8B

Q34004009-2F8CBD8A-90D2-4ADC-A6DB-08C28037C023

Q34004009-36554BB9-EFEF-4909-BB30-41BF397C7283

Q34004009-37DCA1FE-0DAB-470C-96F4-0F1C92A0B435

Q34004009-6A73AA10-247A-4CB3-B592-C4815EA2CB3C

Q34004009-74020460-E244-414D-A3EC-B08376DF8987

Q34004009-983170D9-A55D-4D3D-BDCC-CC3164D2A642

Q34004009-A21C09BA-B49B-43D4-88DF-BD28CD932E67

Q34004009-B67A4C45-BF5D-4366-8CB1-F88814BE56E7

P304

Q34004009-A0B2EF24-126B-4DF4-9F1F-F2CDE53B0AC6

P31

Q34004009-C7A2E864-F15D-494B-8161-8F7DCE8D4C74

P356

Q34004009-2D1C4D02-2265-4F55-A95C-7643F14124C5

P407

Q34004009-DD64D72F-07B5-4150-BB87-7DD7127BD80F

P433

Q34004009-022BC6E8-B840-4E0A-A733-AC0A48C1CACE

P478

Q34004009-EA4E87B6-BF1B-44F4-A1AD-4BCAEBD107BF

P577

Q34004009-3714235E-08E2-4BB0-BBC3-B9E865E875F7

P698

Q34004009-CA68B69F-1D43-4519-B019-A9603C09147E

P921

Q34004009-3C8B56C7-4114-4CC8-AFE3-F16A182CA678

P356

J.VACCINE.2007.04.008

P1433

P1476

Phase I/II studies to evaluate ...... rus vaccine in healthy adults.

@en

P2093

Alex Bollen

http://www.w3.org/2001/XMLSchema#string

Etienne M Sokal

http://www.w3.org/2001/XMLSchema#string

Francoise Denamur

http://www.w3.org/2001/XMLSchema#string

Françoise Smets

http://www.w3.org/2001/XMLSchema#string

Gary Dubin

http://www.w3.org/2001/XMLSchema#string

Martine Denis

http://www.w3.org/2001/XMLSchema#string

Michel Moutschen

http://www.w3.org/2001/XMLSchema#string

Michèle Haumont

http://www.w3.org/2001/XMLSchema#string

Pascal Peeters

http://www.w3.org/2001/XMLSchema#string

Pasqualina Mazzu

http://www.w3.org/2001/XMLSchema#string

P304

4697-4705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2007.04.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17485150

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus